[31] Spigel, D.R., Townley, P.M., Waterhouse, D.M., Fang, L., Adiguzel, I., Huang, J.E., Karlin, D.A., Faoro, L., Scappaticci, F.A. and Socinski, M.A. (2011) Randomized Phase II Study of Bevacizumab in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer:
Results from the SALUTE Trial. Journal of Clinical Oncology, 29, 2215-2222. http://dx.doi.org/10.1200/
JCO.2010.29.3423 [32] Mountzios, G., Emmanouilidis, C., Vardakis, N., Kontopodis, E., Hatzidaki, D., Popis, E., et al. (2012) Paclitaxel Plus Bevacizumab in Patients with Chemoresistant Relapsed Small Cell Lung Cancer as Salvage Treatment: A Phase II Multicenter Study of the Hellenic Oncology Research Group. Lung Cancer, 77, 146-150. http://dx.doi.org/10.1016/j.lungcan.2012.02.002 [33] Arnold, A.M., Seymour, L., Smylie, M., Ding, K.Y., Ung, Y., Findlay, B., et al. (2007) Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients after Complete or Partial Response to Induction Chemotherapy with or without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. Journal of Clinical Oncology, 25, 4278-4284.
http://dx.doi.org/10.1200/JCO.2007.12.3083 [34] Ramalingam, S.S., Belani, C.P., Mack, P.C., Vokes, E.E., Longmate, J., Govindan, R., Koczywas, M., Ivy, S.P. and Gandara, D.R. (2010) Phase II Study of Cediranib [AZD 2171], an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer [National Cancer Institute #7097]. Journal of Thoracic Oncology, 5, 1279-1284.
http://dx.doi.org/10.1097/JTO.0b013e3181e2fcb0 [35] Rigas, J.R., Denham, C.A., Rinaldi, D., Moore, T., Smith II, J.W., Winston, R.D. and Humphrey, R. (2003) O-107 Adjuvant Targeted Therapy in Unresectable Lung Cancer: The Results of Two Randomized Placebo-Controlled Trials of Bay 12-9566, a Matrix Metalloproteinase Inhibitor [MMPI]. Lung Cancer, 41, S34. http://dx.doi.org/10.1016/S0169-5002(03)91765-X [36] Shepherd, F.A., Giaccone, G., Seymour, L., Debruyne, C., Bezjak, A., Hirsh, V., Smylie, M., Rubin, S., Martins, H., Lamont, A., Krzakowski, M., Sadura, A. and Zee, B. (2002) Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Marimastat after Response to First-Line Chemotherapy in Patients with Small-Cell Lung Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. Journal of Clinical Oncology, 20, 4434-4439. http://dx.doi.org/10.1200/JCO.2002.02.108 [37] Pujol, J.L., Breton, J.L., Gervais, R., Tanguy, M.L., Quoix, E., David, P., Janicot, H., Westeel, V., Gameroff, S., Genève, J. and Maraninchi, D. (2007) Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer after Response to Chemotherapy: An Intergroup Study FNCLCC cleo04 IFCT 00-01. Journal of Clinical Oncology, 25, 3945-3951. http://dx.doi.org/10.1200/JCO.2007.11.8109 [38] Lee, S.M., Woll, P.J., Rudd, R., Ferry, D., O’Brien, M., Middleton, G., Spiro, S., James, L., Ali, K., Jitlal, M. and Hackshaw, A. (2009) Anti-Angiogenic Therapy Using Thalidomide Combined with Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of the National Cancer Institute, 101, 1049-1057. http://dx.doi.org/10.1093/jnci/djp200 [39] Sharma, N., Pennell, N., Nickolich, M., Halmos, B., Ma, P., Mekhail, T., Fu, P. and Dowlati, A. (2014) Phase II Trial of Sorafenib in Conjunction with Chemotherapy and as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer. Investigational New Drugs, 32, 362-368.
http://dx.doi.org/10.1007/s10637-013-0061-6 [40] Ready, N.E., Pang, H.H., Gu, L., Otterson, G.A., Thomas, S.P., Miller, A.A., et al. (2013) Chemotherapy with or without Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer: A Randomized, Placebo Controlled Phase II Study CALGB 30504 [ALLIANCE]. Journal of Clinical Oncology, 31, 7506. [41] Heist, R.S., Fain, J., Chinnasami, B., Khan, W., Molina, J., Brainerd, V., Leopold, L. and Lynch, T. (2009) A Phase I/II [P1/P2] Study of AT-101 in Combination with Topotecan[t] in Patients with Relapsed or Refractory Small Cell Lung Cancer [SCLC] after Prior Platinum-Containing First-Line Chemotherapy. Journal of Clinical Oncology, 27, 8106. [42] Lara Jr., P.N., Chansky, K., Davies, A.M., Franklin, W.A., Gumerlock, P.H., Guaglianone, P.P., Atkins, J.N., Farneth, N., Mack, P.C., Crowley, J.J. and Gandara, D.R. (2006) Bortezomib [PS-341] in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial [S0327]. Journal of Thoracic Oncology, 1, 996-1001. http://dx.doi.org/10.1097/01243894-200611000-00013 [43] Gandhi, L., Chu, Q.S., Stephenson, J., Johnson, B.E., Govindan, R., Bonomi, P., Eaton, K., Fritsch, H., Munzert, G. and Socinski, M. (2009) An Open Label Phase II Trial of the Plk1 Inhibitor Bi 2536, in Patients with Sensitive Relapse Small Cell Lung Cancer [SCLC]. Journal of Clinical Oncology, 27, 8108. [44] Prystowsky, M., Feeney, K., Kawachi, N., Montagna, C., Willmott, M., Wasson, C., Antkowiak, M., Loudig, O. and Parish, J. (2013) Inhibition of Plk1 and Cyclin B1 Expression Results in Panobinostat-
Induced G2 Delay and Mitotic Defects. Scientific Reports, 3, 2640. http://dx.doi.org/10.1038/srep026
40 [45] Crisanti, M.C., Wallace, A.F., Kapoor, V., Vandermeers, F., Dowling, M.L., Pereira, L.P., et al. (2009) The HDAC Inhibitor Panobinostat [LBH589] Inhibits Mesothelioma and Lung Cancer Cells in Vitro and in Vivo with Particular Efficacy for Small Cell Lung Cancer. Molecular Cancer Therapeutics, 8, 2221-2231. http://dx.doi.org/10.1158/1535-7163.MCT-09-0138 [46] Minami, T., Kijima, T., Kohmo, S., Arase, H., Otani, Y., Nagatomo, I., et al. (2013) Overcoming Chemoresistance of Small-Cell Lung Cancer through Stepwise HER2-Targeted Antibody-Dependent Cell-Mediated Cytotoxicity and VEGF-Targeted Antiangiogenesis. Scientific Reports, 3, 2669. http://dx.doi.org/10.1038/srep02669 [47] Abidin, A.Z., Garassino, M.C., Califano, R., Harle, A. and Blackhall, F. (2010) Targeted Therapies in Small Cell Lung Cancer: A Review. Therapeutic Advances in Medical Oncology, 2, 25-37. http://dx.doi.org/10.1177/1758834009356014 [48] Giaccone, G., Debruyne, C., Felip, E., Chapman, P.B., Grant, S.C., Millward, M., Thiberville, L., D’addario, G., Coens, C., Rome, L.S., Zatloukal, P., Masso, O. and Legrand, C. (2005) Phase III Study of Adjuvant Vaccination with Bec2/Bacille Calmette-Guerin in Responding Patients with Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 0897
1-08971B; Silva Study). Journal of Clinical Oncology, 23, 6854-6864. http://dx.doi.org/10.1200/JCO.
2005.17.186 [49] Antonia, S.J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.H., Menander, K., Chada, S. and Gabrilovich, D.I. (2006) Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer. Clinical Cancer Research, 12, 878-887. [50] Kola, I. and Landis, K. (2004) Can the Pharmaceutical Industry Reduce Attrition Rates? Nature Reviews Drug Discovery, 3, 711-715. [51] Carden, C.P., Sarker, D., Postel-Vinay, S., Yap, T.A., Attard, G., Banerji, U., et al. (2010) Can Molecular Biomarker-Based Patient Selection in Phase I Trials Accelerate Anticancer Drug Development? Drug Discovery Today, 15, 88-97. http://dx.doi.org/10.1016/j.drudis.2009.11.006 [52] Stratmann, A.T., Fecher, D., Wangorsch, G., Gottlich, C., Walles, T., Walles, H., Dandekar, T., Dandekar, G. and Nietzer, S.L. (2013) Establishment of a Human 3D Lung Cancer Model Based on a Biological Tissue Matrix Combined with a Boolean in Silico Model. Molecular Oncology, 8, 351-365. http://dx.doi.org/10.1016/j.molonc.2013.11.009

  
comments powered by Disqus
ALC Subscription
E-Mail Alert
ALC Most popular papers
Publication Ethics & OA Statement
ALC News
Frequently Asked Questions
Recommend to Peers
Recommend to Library
Contact Us

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.